ScreenerHero

XOMA XOMA Corporation

Data unavailable
NAS · US · Healthcare · Biotechnology · xoma.com
40.17USD0.00%Mkt Cap: 710.16M $P/E: 25.59

XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States, Switzerland, the Asia Pacific, and Australia. It has a portfolio of economic rights to future potential milestone and royalty paymen…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$129.20BUSDP/E 29.7
MRNA
Moderna, Inc.
$89.83BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.86BUSDP/E 18.5
ARGX
argenx SE
$51.88BUSDP/E 31.4
ARGX
argenx SE
$49.79BUSDP/E 32.4
UCB
UCB SA
$42.17BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$40.67BUSD
ONC
BeOne Medicines AG
$40.33BUSDP/E 63.4
RPRX
Royalty Pharma plc
$32.90BUSDP/E 30.3
ALNY
Alnylam Pharmaceuticals, Inc.
$31.13BUSDP/E 39.2
ROIV
Roivant Sciences Ltd.
$25.60BUSD
BNTX
BioNTech SE
$24.36BUSD
INCY
Incyte Corporation
$22.86BUSDP/E 14.4
GMAB
Genmab A/S
$22.79BUSDP/E 29.2
GMAB
Genmab A/S
$21.90BUSDP/E 30.2
INSM
Insmed Incorporated
$21.97BUSD
ASND
Ascendis Pharma A/S
$15.08BUSDP/E 17.6
EXEL
Exelixis, Inc.
$14.83BUSDP/E 18.9
JAZZ
Jazz Pharmaceuticals plc
$14.18BUSDP/E 15.0
SMMT
Summit Therapeutics Inc.
$14.03BUSD

Key Statistics

Company
Market Cap710.16M USD
Enterprise Value562.48M USD
Revenue (TTM)48.55M USD
Gross Profit48.09M USD
Net Income (TTM)31.71M USD
Revenue/Share4.03 USD
Last Price40.17 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees14
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)25.59
P/E (Forward)18.77
PEG—
EV/EBITDA67.81
EV/Revenue11.58
P/S14.63
P/B5.15
EPS (TTM)1.57
EPS (Forward)2.14
52W Range
22.2978% of range45.20
52W High45.20 USD
52W Low22.29 USD
Profitability
Gross Margin99.04%
Oper. Margin-3.90%
EBITDA Margin17.08%
Profit Margin271.97%
ROE37.78%
ROA11.63%
Growth
Revenue Growth-22.60%
Earnings Growth207.90%
Cash Flow & Leverage
Operating CF2.87M USD
CapEx (TTM)20.73M USD
FCF Margin-26.92%
FCF Yield-1.84%
Net Debt38.64M USD
Net Debt/EBITDA4.66
Balance Sheet
Debt/Equity1.57
Current Ratio3.59
Quick Ratio3.31
Book Value/Sh7.79 USD
Cash/Share6.87 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div DateJan 3, 2025
Pay Date—
Splits
Last Split1:20
Split DateOct 18, 2016
Analyst Consensus
Rating3.0 (Hold)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)39.00 USD
Upside (mean)-2.9%
Target Range39.00 USD – 39.00 USD
# Analysts1
Ownership
Shares Out.17.68M
Float4.80M
Insiders2.33%
Institutions85.33%
Short Interest
Short Ratio6.4d
Short % Float9.29%
Short % Out.5.18%
Shares Short914.94K
Short (prev mo.)852.05K
Technical
SMA 5041.95 (-4.2%)
SMA 20033.57 (+19.7%)
Beta0.86
S&P 52W Chg20.20%
Avg Vol (30d)258.87K
Avg Vol (10d)763.86K
Technical Indicators
RSI (14)35.3
MACD-0.4150
MACD Signal-0.0430
MACD Hist.-0.3720
BB Upper45.01 USD
BB Middle41.93 USD
BB Lower38.86 USD
BB Width14.66%
ATR (14)0.5578 USD
Vol Ratio (20d)0.00x